Horizon Therapeutics has launched its #RAREis Representation program aimed at increasing diversity, equity, and inclusion among patients with rare diseases. There are about 400 million people worldwide living with a rare disease; for many of them, access to diagnosis, care, and treatments can be challenging. Accessing better care depends on…
News
Five children in India who developed or had a relapse of atypical hemolytic uremic syndrome (aHUS) in the summer of 2021 all appeared to have experienced mild COVID-19 infection, which is thought to have triggered the rare immune system disorder. Those are the findings of a recent report by…
Bionews, the publisher of this website, hosted a virtual panel discussion on Rare Disease Day 2022, taking a deeper dive into what it’s like to live with a rare disease, including conversations about advocacy, mental health, survivor’s guilt, treatment of minority patients, and more. The Monday event, “A…
A rare disease puts an economic burden on the patients, families, and caregivers that it affects, and will no doubt be an integral part of discussions on Rare Disease Day 2022, which brings international awareness about the more than 300 million people living with rare disorders. Part of that…
The nonprofit RARE-X is creating an easily-accessible, centralized data hub for all rare disease patient data that can help researchers answer questions about existing disorders, discover new ones, and work toward finding treatments. It was spun out of the work that Nicole Boice, founder and chief engagement officer of…
It’s been nearly a year since the EveryLife Foundation for Rare Diseases released its expansive report finding the total economic burden of rare disorders in the U.S. to be nearly $1 trillion.
A woman carrying specific gene variants placing her at increased risk of developing atypical hemolytic uremic syndrome (aHUS) was diagnosed with the disease following COVID-19 vaccination, as described in a recent case report. “Given the short time lapse between vaccination … and the clinical manifestations, we believe that vaccine…
Since 2008, Rare Disease Day — the last day of February — has brought together patients, caregivers, family members, friends, and advocates from around the world to raise awareness and improve equity for the more than 7,000 known rare diseases that affect more than 300 million people. In 2022, the…
Ultomiris (ravulizumab) was reportedly used for the first time to control atypical hemolytic uremic syndrome (aHUS) in a patient who received a kidney transplant from a living donor, according to a group of doctors in Germany. “We provide first evidence for the efficacy of [Ultomiris] to prevent recurrence…
Soliris (eculizumab) prevented disease recurrence in a small group of patients with primary atypical hemolytic uremic syndrome (aHUS) after they underwent kidney transplantation, a recent study has found. The study, “Efficacy and Safety of Eculizumab in Kidney Transplant Patients With Primary Atypical Hemolytic-Uremic Syndrome,” was published in…
Recent Posts
- Patients need more help to pay for rare disease treatment
- Man’s psoriasis triggers kidney failure, aHUS in rare overlap
- How inflammation from multiple conditions led to an eye emergency
- Early treatment critical in aHUS to prevent lasting kidney damage
- I struggle daily with deconditioning from my multiple illnesses
- Complement inhibitors show edge over plasma at stopping aHUS relapses
- Boy’s kidney issues resolve after Soliris treatment: Case report
- I’m learning to say, ‘There’s always tomorrow’ when I’m feeling guilty
- Rare aHUS after kidney transplant successfully treated with Soliris
- Study describes ‘unusual trilogy’ of aHUS, Fabry disease, heart disorder